Microtubule-Associated Protein tau (MAPT) Peptide
MAPT
Reactivity: Human
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN979811
Quick Overview for Microtubule-Associated Protein tau (MAPT) Peptide (ABIN979811)
Target
MAPT
(Microtubule-Associated Protein tau (MAPT))
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-MAPT antibody (Catalog #: ARP48103_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- MAPT (Microtubule-Associated Protein tau (MAPT))
-
Background
-
MAPT is differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. The mutations in the gene have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Alias Symbols: DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, TAU
Protein Interaction Partner: YWHAZ,GSK3B,AATF,ABL1,ACTB,APOE,CALM1,CAMK2A,CASP1,CASP3,CASP6,CASP7,CASP8,CDK1,CDK5,CDK5,CDK5,FLJ10357,FYN,GSK3A,GSK3B,HSPA8,MAPK12,MAPT,MARK1,MARK4,OGT,PHKG1,PIN1,PKN1,PPP2CA,PPP2CB,PPP2R5A,PPP5C,PRKCD,PSEN1,RPS6KA3,RPS6KB1,S100B,SNCA,SPTB,STAU1,STUB1,STXBP1,TUBA4A,TUBB,UBB,USP9Y,YWHAB,YWHAZ,AATF,APOE,BAG1,CALM1,FYN,HSPA8,MARK4,PARK2,PIN1,PSEN1,S100B,SNCA,STUB1,STXBP1,UBC,YWHAB,YWHAB,YWHAZ
Protein Size: 441 -
Molecular Weight
- 46 kDa
-
Gene ID
- 4137
-
NCBI Accession
- NM_005910, NP_005901
Target
-
You are here:
